Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Mitogen-activated protein kinase 14 | ||
| Ligand | BDBM50357903 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_787640 (CHEMBL1918093) | ||
| IC50 | 0.490000±n/a nM | ||
| Citation |  Lumeras, W; Vidal, L; Vidal, B; Balagué, C; Orellana, A; Maldonado, M; Domínguez, M; Segarra, V; Caturla, F 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase. J Med Chem54:7899-910 (2011) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Mitogen-activated protein kinase 14 | |||
| Name: | Mitogen-activated protein kinase 14 | ||
| Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta | ||
| Type: | Serine/threonine-protein kinase | ||
| Mol. Mass.: | 41286.76 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | Q16539 | ||
| Residue: | 360 | ||
| Sequence: |
| ||
| BDBM50357903 | |||
| n/a | |||
| Name | BDBM50357903 | ||
| Synonyms: | CHEMBL1916360 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C25H19Cl3FN3O | ||
| Mol. Mass. | 502.795 | ||
| SMILES | [O-][n+]1ccc2c(cc(nc2c1-c1c(Cl)cccc1Cl)C1CCNCC1)-c1ccc(F)cc1Cl |(-9.19,-39.37,;-7.86,-38.61,;-7.86,-37.06,;-6.53,-36.29,;-5.19,-37.05,;-3.86,-36.28,;-2.52,-37.06,;-2.52,-38.6,;-3.87,-39.37,;-5.2,-38.6,;-6.53,-39.38,;-6.52,-40.91,;-7.86,-41.68,;-9.19,-40.91,;-7.85,-43.22,;-6.52,-43.99,;-5.18,-43.21,;-5.19,-41.67,;-3.86,-40.89,;-1.19,-39.37,;-1.2,-40.91,;.13,-41.69,;1.47,-40.93,;1.47,-39.38,;.14,-38.6,;-3.86,-34.75,;-2.52,-33.98,;-2.52,-32.44,;-3.86,-31.67,;-3.86,-30.13,;-5.2,-32.45,;-5.19,-33.98,;-6.52,-34.76,)| | ||
| Structure | 
| ||